Mixed Phase IIb results for Santhera's Parkinson drug
This article was originally published in Scrip
Executive Summary
Santhera Pharmaceuticals' Phase IIb trial of fipamezole (JP-1730) failed to meet its primary endpoint, but the drug did show promise in a subpopulation of Parkinson's patients. Preliminary results of the trial indicate that fipamezole is safe and well tolerated, says the Swiss company.